ALN-PCSsc: Phase I data

A single-blind, placebo-controlled, U.K. Phase I trial in 69 healthy subjects on or off statins with elevated baseline LDL-C levels of >100 mg/dL showed that single and multiple doses of subcutaneous ALN-PCSsc were generally well tolerated with no serious adverse events reported. Mean maximum percent PCSK9

Read the full 462 word article

How to gain access

Continue reading with a
two-week free trial.